anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Diagram

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 23,622
Current window 12,361-12,390
Pages 788
Rows per page 30
Component: Diagramclear collectionreset all
18 30 60

Component

12,361-12,390 of 23,622

filter-aware
07
The diagram uses a hub-and-spoke style layout with three outer pillars (Entrepreneurial Culture, Ensemble of Complementary Houses, Group Strength) supporting the central core.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Beat · Complication1 hit
13
The slide uses a hub-and-spoke diagram to illustrate the ownership structure of Kering.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Beat · Problem & Complication1 hit
19
The slide uses a hub-and-spoke diagram to illustrate committee structure.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Beat · Problem & Complication1 hit
20
The diagram uses a hub-and-spoke layout to show the Audit Committee at the center of five key oversight activities.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Beat · Problem & Complication1 hit
28
The slide outlines the compensation structure for the Chairman, CEO, and Group Managing Director.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Beat · WhatLoop · Golden Circle1 hit
36
The slide uses a hub-and-spoke style diagram to organize achievements under three thematic pillars.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Beat · New Bliss1 hit
38
The slide uses a hierarchical org chart to demonstrate how sustainability is integrated into the board, executive committee, and operational teams.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Beat · New Bliss1 hit
41
The slide uses a matrix structure to show coverage of environmental impacts across supply chain tiers, highlighting legal reporting vs additional impacts.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations 1 hit
54
The slide uses a hub-and-spoke diagram for The Fashion Pact and a descriptive list for the Watch & Jewellery Initiative.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
68
The central hub contains the core message, while spokes represent specific engagement areas.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations 1 hit
74
The slide uses a funnel-like diagram to show how strategic goals are enabled by a core of mindset, roles, processes, and systems, supported by specific digital platforms.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations 1 hit
05
The slide uses a 3-step process diagram to illustrate the biological mechanism of protein degradation.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · Interest1 hit
07
Uses a timeline-style visual to contrast established modalities with the emerging TPD field.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · InterestLoop · Logic Chain1 hit
15
The slide uses a split-timeline approach with drug development milestones above the line and corporate/financing events below.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · DesireLoop · Logic Chain1 hit
26
The slide outlines a clinical trial methodology involving healthy volunteers (HV) and patients across SAD and MAD cohorts.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
29
The slide uses a process flow diagram to explain the experimental procedure.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
47
The slide uses a process flow diagram to map biological signaling pathways from upstream initiation to downstream clinical manifestations.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
48
Includes a biological pathway diagram and three charts demonstrating efficacy in inhibiting pNFkB, cytokines, and IRAK4 degradation.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
50
The slide illustrates a biological pathway diagram showing how IRAKiMiDs degrade both IRAK4 and IMiD substrates to inhibit proliferation and survival in cancer cells.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
55
The diagram illustrates a multi-arm clinical trial design with dose escalation (DL1, DL2, DLx) leading to MTD/RP2D expansion cohorts for various indications, including combination therapy arms.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
56
The diagram maps clinical trial inputs (left) to regulatory outcomes (right).Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
64
The slide uses a process flow diagram to show the progression from initial dose levels (DL1, DL2, DLx) to expansion cohorts for various cancer types and combination therapies.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
65
The slide uses a process-flow diagram to map clinical trial phases to regulatory approval outcomes.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
76
The chart is a waterfall plot showing dependency scores across various cell lines, illustrating that p53-wildtype cells are highly dependent on MDM2.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
77
The slide uses a biological pathway diagram to contrast two therapeutic modalities (inhibitor vs. degrader) in the context of p53 regulation.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
80
Shows that KT-253 (degrader) induces apoptosis even after short exposure, whereas DS-3032 (SMI) does not.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
83
Uses a Venn diagram to segment potential patient populations for MDM2 degradation therapy.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
87
Uses a three-column structure to categorize target classes and corresponding TPD solutions (Heterobifunctional Degraders, Molecular Glues).Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
93
The slide uses a process flow diagram for the fragment-based optimization and a heatmap for the covalent ligand screening.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
95
The slide uses a process flow: MoA description -> Preclinical data (dog) -> Human prediction model.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit